Sight Sciences (NASDAQ:SGHT) CFO James Rodberg Sells 7,231 Shares of Stock

Key Points

• CFO James Rodberg sold 7,231 shares on April 6 at an average price of $3.55 under a pre-arranged Rule 10b5-1 plan, trimming his stake by 3.04% to 230,939 shares (about $819,833).
• Sight Sciences reported Q results with EPS of ($0.08) beating estimates and revenue of $20.39M; the stock trades near $3.50 with a market cap of roughly $189M, a 52-week range of $2.14–$9.24, and a negative P/E of -4.67.
• Analysts are mixed: the consensus rating is Hold with an average target of $8.31, made up of 5 Buys, 3 Holds and 1 Sell.

Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) CFO James Rodberg sold 7,231 shares of the firm's stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $3.55, for a total value of $25,670.05. Following the completion of the transaction, the chief financial officer owned 230,939 shares of the company's stock, valued at approximately $819,833.45. This represents a 3.04% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

James Rodberg also recently made the following trade(s):

• On Friday, January 16th, James Rodberg sold 2,616 shares of Sight Sciences stock. The stock was sold at an average price of $6.62, for a total value of $17,317.92.

Sight Sciences Price Performance

NASDAQ SGHT traded up $0.02 during trading hours on Thursday, hitting $3.50. The company had a trading volume of 115,412 shares, compared to its average volume of 312,645. Sight Sciences, Inc. has a 52 week low of $2.14 and a 52 week high of $9.24. The firm has a 50 day simple moving average of $4.67 and a 200 day simple moving average of $5.74. The company has a debt-to-equity ratio of 0.63, a quick ratio of 9.52 and a current ratio of 10.22. The firm has a market capitalization of $189.02 million, a price-to-earnings ratio of -4.67 and a beta of 2.50.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its earnings results on Wednesday, March 4th. The company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.07. Sight Sciences had a negative return on equity of 55.72% and a negative net margin of 49.67%.The business had revenue of $20.39 million during the quarter, compared to the consensus estimate of $20.35 million. Equities research analysts expect that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On Sight Sciences

Several hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC bought a new stake in Sight Sciences during the fourth quarter valued at approximately $109,000. Invesco Ltd. bought a new stake in Sight Sciences during the fourth quarter valued at approximately $2,791,000. Occudo Quantitative Strategies LP bought a new stake in Sight Sciences during the fourth quarter valued at approximately $185,000. Millennium Management LLC lifted its position in Sight Sciences by 99.4% during the fourth quarter. Millennium Management LLC now owns 266,919 shares of the company's stock valued at $2,117,000 after purchasing an additional 133,073 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in Sight Sciences by 4.5% during the fourth quarter. Bridgeway Capital Management LLC now owns 100,733 shares of the company's stock valued at $799,000 after purchasing an additional 4,300 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have commented on the company. William Blair restated an "outperform" rating on shares of Sight Sciences in a research note on Thursday, March 5th. UBS Group cut their target price on Sight Sciences from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Friday, March 6th. Raymond James Financial set a $9.00 target price on Sight Sciences in a research note on Monday, January 5th. Stifel Nicolaus lifted their price target on Sight Sciences from $6.00 to $8.00 and gave the company a "buy" rating in a research report on Monday, March 2nd. Finally, Cantor Fitzgerald set a $8.00 price target on Sight Sciences in a research report on Monday, March 2nd. Five research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $8.31.

About Sight Sciences

Sight Sciences, Inc is a medical device company focused on developing and commercializing minimally invasive treatments for chronic eye diseases. The company's flagship products include the OMNI® Surgical System, designed to address multiple points of resistance in the eye's natural drainage pathways to lower intraocular pressure in glaucoma patients, and the TearCare® System, a wearable device for treating meibomian gland dysfunction and dry eye disease through targeted thermal pulsation therapy.

Since its founding in 2012 and subsequent listing on the NASDAQ under the ticker SGHT, Sight Sciences has pursued a strategy of combining research-driven product development with a direct sales force model.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.